SG11201804037XA - Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide) - Google Patents
Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide)Info
- Publication number
- SG11201804037XA SG11201804037XA SG11201804037XA SG11201804037XA SG11201804037XA SG 11201804037X A SG11201804037X A SG 11201804037XA SG 11201804037X A SG11201804037X A SG 11201804037XA SG 11201804037X A SG11201804037X A SG 11201804037XA SG 11201804037X A SG11201804037X A SG 11201804037XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- glycolide
- lactide
- poly
- aromatic
- Prior art date
Links
- 239000000243 solution Substances 0.000 title abstract 4
- 238000002347 injection Methods 0.000 title abstract 3
- 239000007924 injection Substances 0.000 title abstract 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 title abstract 3
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 title abstract 2
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229920001577 copolymer Polymers 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- 108010002459 HIV Integrase Proteins 0.000 abstract 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property - Organization International Bureau res., 00) ..... ..s,„,„.1 (43) International Publication Date r 26 May 2017(26.05.2017) WIPO I PCT ID Hit (10) WO International 2017/084973 1111111111111111111111111111111111111111111111111111111111111t111111111111111 Publication Number Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/00 (2006.01) A61K 47/34 (2017.01) kind of national protection available): AE, AG, AL, AM, A61K 47/22 (2006.01) A61K 31/505 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP2016/077402 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 11 November 2016 (11.11.2016) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/255,866 16 November 2015 (16.11.2015) US (84) Designated States (unless otherwise indicated, for every 15197777.4 3 December 2015 (03.12.2015) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: EVONIK ROHM GMBH [DE/DE]; TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Kirschenallee, 64293 Darmstadt (DE). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (72) Inventors: WINDHAB, Norbert; UbierstraBe 20, 65719 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Hofheim (DE). JABER, Rima; Rudolfstr. 4, 60327 Frank- SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, fort (DE). SCHRODER, Axel; Geschwister-Scholl-Str. 4, 64354 Reinheim (DE). BURTON, Kevin; 616 Founders GW, KM, ML, MR, NE, SN, TD, TG). Park Drive West, Hoover, Alabama 35226 (US). TICE, Published: Tom; 5317 Mountain Park Indian Circle, Springs, 21(3)) with international search report (Art Alabama 35124 (US). (74) Agent: GOTTSCHALK, Michael; Evonik Industries AG, CI-IPM-PAT, Postcode 84/339, Rodenbacher Chaussee 4, 63457 Hanau (DE). (54) Title: INJECTION SOLUTION COMPRISING A NON-NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITOR AND POLY(LACTIDE-CO-GLYCOLIDE) Fig 1 2 1,8 1,6 1,4 E 1,2 11 13 r i i 1 .4t 0 u , -3 , 0 8 en 0,6 IN • R 752 - 5 0,4 Cr\ /a it 0,2 Ge 0 I - • R 752-15 O 0 1000 2000 3000 4000 5000 IN time [min] 11 C (57) : The invention is concerned with an injection solution, comprising an organic solvent, a copolymer, which is a ei poly(lactide-co-glycolide) dissolved in the organic solvent and a pharmaceutical active ingredient which is non-nucleoside inhibitor 0 of the HIV reverse transcriptase or of the HIV integrase, which contains aromatic and heterocyclic aromatic or aromatic and hetero - cyclic aromatic and aliphatic heterocyclic groups, wherein the content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562255866P | 2015-11-16 | 2015-11-16 | |
| EP15197777 | 2015-12-03 | ||
| PCT/EP2016/077402 WO2017084973A1 (en) | 2015-11-16 | 2016-11-11 | Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804037XA true SG11201804037XA (en) | 2018-06-28 |
Family
ID=54780205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804037XA SG11201804037XA (en) | 2015-11-16 | 2016-11-11 | Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide) |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10406098B2 (en) |
| EP (1) | EP3377039B1 (en) |
| JP (1) | JP6835841B2 (en) |
| KR (1) | KR102673927B1 (en) |
| CN (1) | CN108289844B (en) |
| CA (1) | CA3005313C (en) |
| IL (1) | IL259303B2 (en) |
| SG (1) | SG11201804037XA (en) |
| WO (1) | WO2017084973A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020128525A1 (en) * | 2018-12-21 | 2020-06-25 | The University Of Liverpool | Nrti therapies |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US6537972B1 (en) | 1997-06-02 | 2003-03-25 | Subsidiary No. 3., Inc. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| US6288234B1 (en) * | 1998-06-08 | 2001-09-11 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| US6565874B1 (en) * | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| US8470359B2 (en) | 2000-11-13 | 2013-06-25 | Qlt Usa, Inc. | Sustained release polymer |
| AP1781A (en) | 2001-11-30 | 2007-09-27 | Pfizer | Controlled release polymeric compositions of bone growth promoting compounds. |
| US20060106043A1 (en) * | 2004-11-08 | 2006-05-18 | Boehringer Ingelheim International Gmbh | Method for treating HIV infection through co-administration of tipranavir and etravirine |
| EA014914B1 (en) * | 2006-01-20 | 2011-02-28 | Тиботек Фармасьютикалз Лтд. | Long term treatment of hiv infection |
| EP2201028A2 (en) * | 2007-09-25 | 2010-06-30 | Trimeris, Inc. | Novel methods of synthesis for therapeutic antiviral peptides |
| SG172398A1 (en) * | 2008-12-24 | 2011-07-28 | Tibotec Pharm Ltd | Implantable devices for treating hiv |
| EP2768544A4 (en) * | 2011-10-17 | 2015-06-24 | Poly Med Inc | Absorbable in situ gel-forming system, method of making and use thereof |
| AR099428A1 (en) * | 2014-02-14 | 2016-07-20 | Aicuris Gmbh & Co Kg | COMBINATIONS OF PHARMACEUTICAL ACTIVE PRINCIPLES WITH TRI-BASED COMPUTERS (IET) ARIL PIRAZOLES |
| PL3166607T3 (en) * | 2014-07-11 | 2023-02-20 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of hiv |
| CA2961528A1 (en) * | 2014-09-26 | 2016-03-31 | Glaxosmithkline Intellectual Property (No.2) Limited | Long acting pharmaceutical compositions |
-
2016
- 2016-11-11 WO PCT/EP2016/077402 patent/WO2017084973A1/en active Application Filing
- 2016-11-11 SG SG11201804037XA patent/SG11201804037XA/en unknown
- 2016-11-11 JP JP2018525346A patent/JP6835841B2/en not_active Expired - Fee Related
- 2016-11-11 US US15/776,043 patent/US10406098B2/en active Active
- 2016-11-11 CA CA3005313A patent/CA3005313C/en active Active
- 2016-11-11 EP EP16795023.7A patent/EP3377039B1/en active Active
- 2016-11-11 CN CN201680066785.XA patent/CN108289844B/en active Active
- 2016-11-11 KR KR1020187016902A patent/KR102673927B1/en active Active
-
2018
- 2018-05-13 IL IL259303A patent/IL259303B2/en unknown
-
2019
- 2019-07-25 US US16/521,760 patent/US20190343762A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6835841B2 (en) | 2021-02-24 |
| WO2017084973A1 (en) | 2017-05-26 |
| IL259303B (en) | 2022-10-01 |
| US20180318211A1 (en) | 2018-11-08 |
| US10406098B2 (en) | 2019-09-10 |
| CA3005313C (en) | 2024-01-09 |
| JP2018533614A (en) | 2018-11-15 |
| CN108289844B (en) | 2021-09-14 |
| KR20180080322A (en) | 2018-07-11 |
| CN108289844A (en) | 2018-07-17 |
| KR102673927B1 (en) | 2024-06-10 |
| IL259303B2 (en) | 2023-02-01 |
| CA3005313A1 (en) | 2017-05-26 |
| IL259303A (en) | 2018-07-31 |
| US20190343762A1 (en) | 2019-11-14 |
| EP3377039B1 (en) | 2024-01-03 |
| EP3377039A1 (en) | 2018-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804384UA (en) | Geometric configurations for gastric residence systems | |
| SG11201803951QA (en) | Oligonucleotides for inducing paternal ube3a expression | |
| SG11201804368QA (en) | Storage assembly for prosthetic valve | |
| SG11201805120YA (en) | Zika virus vaccine | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201910115XA (en) | Rnai approach for crop pest protection | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
| SG11201804577RA (en) | Fgf21 variants | |
| SG11201809277SA (en) | Random copolymers of acrylates as polymeric friction modifiers, and lubricants containing same | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201908560SA (en) | Heterocyclic compounds useful as dual atx/ca inhibitors | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201804281RA (en) | Suture deployment of prosthetic heart valve | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201407961WA (en) | Risperidone or paliperidone implant formulation | |
| SG11202000136YA (en) | Preparation comprising vonoprazan | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201407368VA (en) | Drug for preventing and/or treating polycystic kidney disease | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201907388YA (en) | Carrier for carrying an ophthalmic lens during its treatment in a bath |